O22 Genetic lesions in multiple myeloma:
โ
R. Hajek; P. Kuglik; R. Zaoralova; H. Greslikova; P. Nemec; J. Smejkalova
๐
Article
๐
2007
๐
Elsevier Science
๐
English
โ 47 KB
note, in 19 patients, remission achieved by bortezomib-based therapy was consolidated by high-dose therapy followed by autologous stem cell transplantation. With a median follow-up time of 11 months (1 27 months), the median progression-free survival of our entire patient population is 13.8 month, w